Novozymes A/S

CPSE:NZYM B Stock Report

Mkt Cap: kr.99.9b

Novozymes Valuation

Is NZYM B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NZYM B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NZYM B (DKK360.6) is trading above our estimate of fair value (DKK350.61)

Significantly Below Fair Value: NZYM B is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NZYM B?

Other financial metrics that can be useful for relative valuation.

NZYM B key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue6x
Enterprise Value/EBITDA19.5x
PEG Ratio3x

Price to Earnings Ratio vs Peers

How does NZYM B's PE Ratio compare to its peers?

The above table shows the PE ratio for NZYM B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average40.3x
CHR Chr. Hansen Holding
42.9x13.6%kr.72.6b
RPM RPM International
27x14.1%US$13.6b
AKZA Akzo Nobel
30x20.6%€12.3b
SY1 Symrise
61.4x19.4%€14.7b
NZYM B Novozymes
31.1x10.5%kr.99.9b

Price-To-Earnings vs Peers: NZYM B is good value based on its Price-To-Earnings Ratio (31.1x) compared to the peer average (40.3x).

Price to Earnings Ratio vs Industry

How does NZYM B's PE Ratio compare vs other companies in the European Chemicals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a21.7%
 n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a21.7%
 n/an/an/a
No more companies

Price-To-Earnings vs Industry: NZYM B is expensive based on its Price-To-Earnings Ratio (31.1x) compared to the European Chemicals industry average (12.4x).

Price to Earnings Ratio vs Fair Ratio

What is NZYM B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NZYM B PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio31.1x
Fair PE Ratio31.4x

Price-To-Earnings vs Fair Ratio: NZYM B is good value based on its Price-To-Earnings Ratio (31.1x) compared to the estimated Fair Price-To-Earnings Ratio (31.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NZYM B forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentkr.360.60
kr.376.54
+4.4%
9.0%kr.430.00kr.326.00n/a13
Dec ’24kr.356.10
kr.376.54
+5.7%
9.0%kr.430.00kr.326.00n/a13
Nov ’24kr.316.40
kr.361.77
+14.3%
11.9%kr.430.00kr.275.00n/a13
Oct ’24kr.284.70
kr.374.00
+31.4%
12.6%kr.460.00kr.275.00n/a13
Sep ’24kr.297.40
kr.373.36
+25.5%
11.4%kr.460.00kr.300.00n/a14
Aug ’24kr.336.60
kr.385.64
+14.6%
11.3%kr.460.00kr.300.00n/a14
Jul ’24kr.317.90
kr.393.50
+23.8%
13.4%kr.520.00kr.300.00n/a14
Jun ’24kr.337.80
kr.396.36
+17.3%
12.6%kr.520.00kr.320.00n/a14
May ’24kr.354.00
kr.395.64
+11.8%
12.2%kr.510.00kr.320.00n/a14
Apr ’24kr.350.90
kr.387.64
+10.5%
12.8%kr.510.00kr.320.00n/a14
Mar ’24kr.341.40
kr.391.93
+14.8%
13.5%kr.520.00kr.320.00n/a14
Feb ’24kr.358.00
kr.393.71
+10.0%
13.8%kr.520.00kr.320.00n/a14
Jan ’24kr.351.90
kr.415.80
+18.2%
13.4%kr.520.00kr.330.00n/a15
Dec ’23kr.425.40
kr.410.19
-3.6%
15.1%kr.540.00kr.330.00kr.356.1016
Nov ’23kr.390.30
kr.423.94
+8.6%
14.8%kr.540.00kr.330.00kr.316.4016
Oct ’23kr.383.20
kr.446.31
+16.5%
15.6%kr.560.00kr.330.00kr.284.7016
Sep ’23kr.414.90
kr.465.69
+12.2%
15.5%kr.560.00kr.350.00kr.297.4016
Aug ’23kr.462.50
kr.451.12
-2.5%
17.1%kr.555.00kr.340.00kr.336.6017
Jul ’23kr.429.50
kr.472.39
+10.0%
16.5%kr.594.00kr.360.00kr.317.9018
Jun ’23kr.435.80
kr.474.61
+8.9%
16.8%kr.594.00kr.360.00kr.337.8018
May ’23kr.494.20
kr.471.83
-4.5%
16.1%kr.594.00kr.360.00kr.354.0018
Apr ’23kr.455.30
kr.459.65
+1.0%
17.2%kr.594.00kr.360.00kr.350.9017
Mar ’23kr.447.00
kr.461.12
+3.2%
17.8%kr.594.00kr.350.00kr.341.4017
Feb ’23kr.441.00
kr.466.89
+5.9%
15.7%kr.594.00kr.359.00kr.358.0018
Jan ’23kr.537.20
kr.458.22
-14.7%
16.0%kr.594.00kr.348.00kr.351.9018
Dec ’22kr.498.60
kr.445.76
-10.6%
15.7%kr.565.00kr.348.00kr.425.4017

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth